Trials / Unknown
UnknownNCT04368182
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients
Detailed description
This study plans to enroll 5 patients to assess the safety of C-TCR055. Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Autologous C-TCR055 | Autologous C-TCR055 administered by intravenous (IV) infusion |
Timeline
- Start date
- 2020-04-13
- Primary completion
- 2020-08-31
- Completion
- 2021-11-30
- First posted
- 2020-04-29
- Last updated
- 2020-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04368182. Inclusion in this directory is not an endorsement.